Redeye endorses AroCell’s clinical widening of its TK210 ELISA kit for the indication of prostate cancer (in the EU). The expansion of intended use supported by the clinical data on said indication is well in line with our expectations and take on the case. We will return with an update focusing on its bid on IDL Biotech, where the matter will be addressed more thoroughly.